-+ 0.00%
-+ 0.00%
-+ 0.00%

Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy

Barchart·07/14/2026 01:00:00
Listen to the news

SHANGHAI, July 14, 2026 /PRNewswire/ -- Today, Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.